What’s Happening With TripAdvisor’s Stock?
January 22nd, 2021 by Trefis Team
TripAdvisor’s stock (NASDAQ: TRIP), currently at around $33 has climbed more than 75% since November as vaccine efficacy data and approvals rolled out. In addition, the Presidential elections and better-than-expected Q3 results added to th...
Alcoa Stock Drops 18% In A Week – What Should You Know?
January 22nd, 2021 by Trefis Team
Alcoa stock (NYSE: AA) dropped 18% in just the last one week. What’s somewhat baffling, at first, is that this happened after the company beat analysts’ expectations in the recently announced Q4 and FY2020 results. by a huge margin. The company ...
Citigroup Stock Is Trading 25% Below Its Fair Value
January 22nd, 2021 by Trefis Team
[Updated 01/22/2021] Citigroup Update Citigroup stock (NYSE: C) is currently trading close to $62, which is 75% above the March 23 lows of the last year and almost 21% below its pre-Covid peak. Trefis estimates Citigroup’s valuation to be...
Should You Buy Johnson & Johnson Stock At $160?
January 22nd, 2021 by Trefis Team
Despite a 45% rise since the March 23 lows of last year, at the current price of around $161 per share we believe that pharmaceuticals bellwether, Johnson & Johnson (NYSE: JNJ), looks attractive and it can see more upside from the current lev...
Should You Book Profits In Pacific Biosciences of California After A Massive 13x Rally?
January 22nd, 2021 by Trefis Team
After a large 13x rise since the March 23 levels of last year, at the current price of around $36 per share we believe Pacific Biosciences of California stock (NASDAQ: PACB), a biotechnology company that develops gene sequencing systems, has reac...
Can Editas Medicine Stock Bounce Back After A 13% Drop In 5 Days ?
January 22nd, 2021 by Trefis Team
Editas Medicine (NASDAQ: EDIT), a biotechnology company focused on developing treatments using gene editing technology, has plunged by 13% over the last 5 trading days, after the company stated its plans to issue 3.5 million shares at $66 per sha...
Is Vaxart Stock Worth The Risk?
January 22nd, 2021 by Trefis Team
Biotech company Vaxart (NASDAQ:VXRT) stock is up by over 11x through the last 12 months rising to levels of around $7 per share, driven by the company’s efforts to develop a Covid-19 vaccine. Vaxart, which focuses on oral recombinant vacc...
Down 25% From December Highs, Is Snowflake Stock A Buy?
January 22nd, 2021 by Trefis Team
Snowflake (NYSE: SNOW) stock trades at levels of around $286, down by roughly 26% from its December highs driven in part by a partial lock-up expiration, which allowed employees to sell a portion of their vested options, and some sell-side analys...
Rio Tinto Rises 36% In 3 Months; Stay Patient To Earn More
January 22nd, 2021 by Trefis Team
Rio Tinto stock (NYSE: RIO) jumped almost 36% in the last three months and currently trades around $80 per share. This rise was driven by the sharp increase of more than 50% in global iron ore prices in three months. Iron ore price per ton incr...
Nio, Li Auto, and Xpeng: Which Chinese EV Stock Is The Best Value?
January 22nd, 2021 by Trefis Team
In late October 2020, we compared the three U.S. listed Chinese electric vehicle (EV) players, Nio (NYSE: NIO), Li Auto (NASDAQ: LI), and Xpeng (NYSE: XPEV). The stocks have had a solid run since then. Over the last three months, Nio stock is up ...
Is Jabil The Best Stock To Play iPhone 12 Cycle Without Overpaying?
January 22nd, 2021 by Trefis Team
Jabil (NYSE: JBL), a manufacturing services company that counts Apple as its largest customer, has seen its stock price rise by over 80% since late 2018, while surging almost 2.5x from its March 2020 lows. The recent gains have been driven by st...
Is Cintas Stock Poised To Rise?
January 21st, 2021 by Trefis Team
Cintas (NASDAQ:CTAS) stock, a provider of corporate identity uniforms through rental and sales programs, has declined 6% year-to-date and also declined around 2% over the last 5 trading days. In comparison, the broader S&P 500 returned around...
Can Altria Stock Surpass Its Pre-Covid Level?
January 21st, 2021 by Trefis Team
We believe Altria stock (NYSE: MO) may be a decent opportunity at the moment. MO trades at $41 currently and is in fact down 18% from $50 at the beginning of 2020. It traded at close to $45 in February 2020, just before the outbreak of the pand...
Lockheed Martin Stock Looks Undervalued
January 21st, 2021 by Trefis Team
Recently, concerns regarding full production of F-35s took a toll on the shares of Lockheed Martin (NYSE: LMT) despite multiple contracts awarded by the U.S. military and the recent bid to acquire Aerojet Rocketdyne. Lockheed Martin’s revenues ...
Can The Gains Continue For Adverum Biosciences After An 18% Move In 5 Days?
January 21st, 2021 by Trefis Team
Adverum Biosciences (NASDAQ: ADVM) stock, a clinical stage gene therapy company focused on serious ocular and rare diseases, has rallied by a solid 18% over the last 5 trading days, after the company disclosed in regulatory filings that CEO Laur...
